Real-world experience with eculizumab in Japanese patients with myasthenia gravis: Post-marketing surveillance data

被引：0
|
作者：
Takahashi, M. [1 ]
Masuda, M. [2 ]
Watanabe, M. [3 ]
Fukamizu, Y. [4 ]
Osawa, T. [4 ]
Kikui, H. [4 ]
Murai, H. [5 ]
机构：
[1] Osaka Univ, Dept Neurol, Grad Sch Med, Osaka, Japan
[2] Tokyo Med Univ, Dept Neurol, Tokyo, Japan
[3] Kyushu Univ, Neurol Inst, Grad Sch Med Sci, Dept Neurol, Fukuoka, Japan
[4] Alex Pharma GK, AstraZeneca Rare Dis, Tokyo, Japan
[5] Int Univ Hlth & Welf, Dept Neurol, Narita, Japan
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-396
引用
收藏
页码：574 / 574
页数：1
相关论文
共 50 条
  • [1] Real-world effectiveness of eculizumab in generalized myasthenia gravis in Japan: 1-year post-marketing surveillance data
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Fukamizu, Yuji
    Osawa, Takehiko
    Kikui, Hidekazu
    Utsugisawa, Kimiaki
    NEUROLOGY, 2022, 98 (18)
  • [2] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
    Murai, Hiroyuki
    Suzuki, Shigeaki
    Hasebe, Miki
    Fukamizu, Yuji
    Rodrigues, Ema
    Utsugisawa, Kimiaki
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [3] REAL-WORLD EXPERIENCE OF ECULIZUMAB FOR MYASTHENIA GRAVIS
    Suh, J.
    Clarke, V.
    Guidon, A.
    MUSCLE & NERVE, 2020, 62 : S119 - S119
  • [4] Safety and Effectiveness of Eculizumab for Patients with Generalized Myasthenia Gravis in Japan: Interim Analysis of Post-Marketing Surveillance
    Murai, H.
    Suzuki, S.
    Hasebe, M.
    Fukamizu, Y.
    Rodrigues, E.
    Utsugisawa, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 485 - 486
  • [5] Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan
    Nishimura, Jun-ichi
    Kawaguchi, Tatsuya
    Ito, Shuichi
    Murai, Hiroyuki
    Shimono, Akihiko
    Matsuda, Takahisa
    Fukamizu, Yuji
    Akiyama, Hirozumi
    Hayashi, Hideo
    Nakano, Takashi
    Maruyama, Shoichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (04) : 419 - 431
  • [6] Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis
    Tokuyasu, Daiki
    Suzuki, Shigeaki
    Uzawa, Akiyuki
    Nagane, Yuriko
    Masuda, Masayuki
    Konno, Shingo
    Kubota, Tomoya
    Samukawa, Makoto
    Sugimoto, Takamichi
    Ishizuchi, Kei
    Oyama, Munenori
    Yasuda, Manato
    Akamine, Hiroyuki
    Onishi, Yosuke
    Suzuki, Yasushi
    Kawaguchi, Naoki
    Minami, Naoya
    Kimura, Takashi
    Takahashi, Masanori P.
    Murai, Hiroyuki
    Utsugisawa, Kimiaki
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (05): : 1338 - 1346
  • [7] Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance (vol 14, pg 1, 2021)
    Murai, H.
    Suzuki, S.
    Hasebe, M.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [8] TWO-YEAR POST-MARKETING SAFETY EXPERIENCE OF ECULIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN THE UNITED STATES
    Muley, S.
    Muppidi, S.
    Levine, T.
    Rodrigues, E.
    Carrillo-Infante, C.
    Howard, J.
    MUSCLE & NERVE, 2020, 62 : S113 - S114
  • [9] Eculizumab in refractory myasthenia gravis: a real-world single-center experience
    Ricciardi, Dario
    Erra, Carmen
    Tuccillo, Francesco
    De Martino, Bernardo Maria
    Fasolino, Alessandra
    Habetswallner, Francesco
    NEUROLOGICAL SCIENCES, 2025, 46 (02) : 951 - 959
  • [10] Real-World experience with efgartigimod in patients with myasthenia gravis
    Fuchs, Lior
    Shelly, Shahar
    Vigiser, Ifat
    Kolb, Hadar
    Regev, Keren
    Schwartzmann, Yoel
    Vaknin-Dembinsky, Adi
    Dori, Amir
    Karni, Arnon
    JOURNAL OF NEUROLOGY, 2024, 271 (06) : 3462 - 3470
12345